Literature DB >> 19900495

Biochemical, pharmaceutical and therapeutic properties of long-acting lithocholic acid derivatized exendin-4 analogs.

Su Young Chae1, Cheng-Hao Jin, Jae Hee Shin, Sohee Son, Tae Hyung Kim, Seulki Lee, Yu Seok Youn, Youngro Byun, Myung-Shik Lee, Kang Choon Lee.   

Abstract

Alterations in the physicochemical characteristics of peptide drugs can transform their biological and pharmaceutical features. In the present study, we explored the potentials of lithocholic acid (LCA)-modified exendin-4 derivatives as novel long-acting GLP-1 receptor agonists. Exendin-4 was modified with lithocholic acid at two lysine residues to produce three derivatives that were obtained by reverse-phase HPLC separation, namely, Lys(12)-LCA-exendin-4 (LCA-M2), Lys(27)-LCA-exendin-4 (LCA-M1), and Lys(12,27)-LCA-exendin-4 (LCA-Di)). The biological, pharmacological, and physicochemical characteristics of these three exendin-4 analogues were then investigated. Although slight reductions in the GLP-1 receptor binding capacity and insulinotropic activity of exendin-4 were observed after derivatization, the mono-LCA substitutions, especially LCA-M1, well-preserved antidiabetic activity in type 2 diabetic mice when administered subcutaneously or intraperitoneally. Furthermore, the pharmacokinetic characteristics were dramatically enhanced, that is, absorption was delayed and elimination half-life was increased (1.6+/-0.4 and 9.7+/-1.4h by exendin-4 and LCA-M1, respectively). The enhanced long-acting characteristics of the derivative was found to be due to albumin binding and nanoparticle formation, and these were verified by the restoration of normoglycemia in type 2 diabetic mice after single injection (>24h, >10 nmol/kg, s.c.) and daily injections (15 nmol/kg/day) maintained normoglycemia for the 4-week administration period. Furthermore, antidiabetic potentials, such as, glucose clearance kinetics and percentage areas occupied by pancreatic beta-cells were also enhanced by long-term LCA-M1 administration. The present study demonstrates that the derivatization of exendin-4 with LCA offers a possible means of producing a long-acting GLP-1 receptor agonist. Copyright 2009 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19900495     DOI: 10.1016/j.jconrel.2009.10.025

Source DB:  PubMed          Journal:  J Control Release        ISSN: 0168-3659            Impact factor:   9.776


  15 in total

Review 1.  Revisiting amino acids and peptides as anti-glycation agents.

Authors:  H Chilukuri; M J Kulkarni; M Fernandes
Journal:  Medchemcomm       Date:  2018-02-12       Impact factor: 3.597

2.  Synthesis and evaluation of [18F]exendin (9-39) as a potential biomarker to measure pancreatic β-cell mass.

Authors:  Yi Wang; Keunpoong Lim; Marc Normandin; Xiaojian Zhao; Gary W Cline; Yu-Shin Ding
Journal:  Nucl Med Biol       Date:  2011-10-26       Impact factor: 2.408

3.  Albumin-coated porous hollow poly(lactic-co-glycolic acid) microparticles bound with palmityl-acylated exendin-4 as a long-acting inhalation delivery system for the treatment of diabetes.

Authors:  Hyunuk Kim; Juho Lee; Tae Hyung Kim; Eun Seong Lee; Kyung Taek Oh; Don Haeng Lee; Eun-Seok Park; You Han Bae; Kang Choon Lee; Yu Seok Youn
Journal:  Pharm Res       Date:  2011-04-07       Impact factor: 4.200

4.  In-vitro and in-vivo difference in gene delivery by lithocholic acid-polyethyleneimine conjugate.

Authors:  Jianping Wang; Fanfei Meng; Bieong-Kil Kim; Xue Ke; Yoon Yeo
Journal:  Biomaterials       Date:  2019-06-21       Impact factor: 12.479

Review 5.  Recent advances in nanomedicine for sepsis treatment.

Authors:  Simseok A Yuk; Diego A Sanchez-Rodriguez; Michael D Tsifansky; Yoon Yeo
Journal:  Ther Deliv       Date:  2018-05-01

6.  Acylation of exenatide by glycolic acid and its anti-diabetic activities in db/db mice.

Authors:  Rongcai Liang; Xiang Li; Renyu Zhang; Yanan Shi; Aiping Wang; Daquan Chen; Kaoxiang Sun; Wanhui Liu; Youxin Li
Journal:  Pharm Res       Date:  2014-02-19       Impact factor: 4.200

7.  Novel coumarin modified GLP-1 derivatives with enhanced plasma stability and prolonged in vivo glucose-lowering ability.

Authors:  Jing Han; Lidan Sun; Xun Huang; Zheng Li; Chenyu Zhang; Hai Qian; Wenlong Huang
Journal:  Br J Pharmacol       Date:  2014-09-05       Impact factor: 8.739

8.  Long-acting inhalable chitosan-coated poly(lactic-co-glycolic acid) nanoparticles containing hydrophobically modified exendin-4 for treating type 2 diabetes.

Authors:  Changkyu Lee; Ji Su Choi; Insoo Kim; Kyung Taek Oh; Eun Seong Lee; Eun-Seok Park; Kang Choon Lee; Yu Seok Youn
Journal:  Int J Nanomedicine       Date:  2013-08-09

Review 9.  Long-acting preparations of exenatide.

Authors:  Yunpeng Cai; Liangming Wei; Liuqing Ma; Xiwen Huang; Anqi Tao; Zhenguo Liu; Weien Yuan
Journal:  Drug Des Devel Ther       Date:  2013-09-05       Impact factor: 4.162

10.  Novel application of hydrophobin in medical science: a drug carrier for improving serum stability.

Authors:  Liqiang Zhao; Haijin Xu; Ying Li; Dongmin Song; Xiangxiang Wang; Mingqiang Qiao; Min Gong
Journal:  Sci Rep       Date:  2016-05-23       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.